-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $14

Benzinga·11/16/2026 13:17:35
Listen to the news
Evercore ISI Group analyst Liisa Bayko maintains Altimmune (NASDAQ:ALT) with a Outperform and lowers the price target from $17 to $14.